Pharmacology | Pharmacy College Media:

The Department of Pharmacology and Toxicology at the University of Basrah organized a scientific seminar titled:
"Casgevy: A Breakthrough in Gene Therapy for Sickle Cell Disease and Beta Thalassemia."

Dr. Shaimaa Nadhem highlighted that Casgevy is the first global treatment utilizing CRISPR-Cas9 technology. This gene-editing therapy increases fetal hemoglobin (HbF) production by silencing the BCL11A gene, directly addressing hereditary blood disorders.

This therapy represents a qualitative leap in modern genetic medicine, significantly reducing pain crises and blood transfusion dependence. It opens new horizons for curative genetic treatments for various multi-faceted hereditary diseases.

❧ ☙